Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2010-10-25
pubmed:abstractText
Asthma comprises a triad of reversible airway obstruction, bronchial smooth muscle cell hyperreactivity to bronchoconstrictors, and chronic bronchial inflammation. Clinical and experimental findings have established eosinophilia as a sign of allergic disorders. In the present investigation, we evaluated the anti-asthmatic effects of schizandrin and its underlying mechanisms in an in vivo murine asthmatic model. To accomplish this, female BALB/c mice were sensitized and challenged with ovalbumin (OVA), and examined for the following typical asthmatic reactions: increased numbers of eosinophils and other inflammatory cells in bronchoalveolar lavage fluid (BALF); production of Th1 cytokines (such as tumor necrosis factor (TNF)-? in BALF); production of Th2 cytokines (such as interleukin IL-4 and IL-5) in BALF; presence of total and OVA-specific immunoglobulins (Ig)E in serum; presence of oxidative stress; hyperplasia of goblet cells in the lung; and marked influx of inflammatory cells into the lung. Our results collectively show that schizandrin exerts profound inhibitory effects on accumulation of eosinophils into the airways and reduces the levels of IL-4, IL-5, IFN-?, and TNF-? in BALF. Additionally, schizandrin suppresses the production of reactive oxygen species (ROS) in a dose-dependent manner, and inhibits goblet cell hyperplasia and inflammatory cell infiltration in lung tissue. Thus, schizandrin has anti-asthmatic effects, which seem to be partially mediated by reduction of oxidative stress and airway inflammation, in a murine allergic asthma model. These results indicate that schizandrin may be an effective novel therapeutic agent for the treatment of allergic asthma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1878-1705
pubmed:author
pubmed:copyrightInfo
Crown Copyright © 2010. Published by Elsevier B.V. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1374-9
pubmed:meshHeading
pubmed-meshheading:20727999-Animals, pubmed-meshheading:20727999-Anti-Asthmatic Agents, pubmed-meshheading:20727999-Asthma, pubmed-meshheading:20727999-Bronchoalveolar Lavage Fluid, pubmed-meshheading:20727999-Cyclooctanes, pubmed-meshheading:20727999-Cytokines, pubmed-meshheading:20727999-Disease Models, Animal, pubmed-meshheading:20727999-Eosinophils, pubmed-meshheading:20727999-Female, pubmed-meshheading:20727999-Goblet Cells, pubmed-meshheading:20727999-Hyperplasia, pubmed-meshheading:20727999-Immunoglobulin E, pubmed-meshheading:20727999-Lignans, pubmed-meshheading:20727999-Lung, pubmed-meshheading:20727999-Mice, pubmed-meshheading:20727999-Mice, Inbred BALB C, pubmed-meshheading:20727999-Oxidative Stress, pubmed-meshheading:20727999-Polycyclic Compounds, pubmed-meshheading:20727999-Reactive Oxygen Species, pubmed-meshheading:20727999-Th1 Cells, pubmed-meshheading:20727999-Th2 Cells
pubmed:year
2010
pubmed:articleTitle
Anti-asthmatic effect of schizandrin on OVA-induced airway inflammation in a murine asthma model.
pubmed:affiliation
Herbal Medicine EBM Research Center, Korea Institute of Oriental Medicine, Yuseong-gu, Daejeon, Republic of Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't